MAPT and Alzheimer disease: Importantly, an AD CSF profile, PET-amyloid and PET-tau burden have been associated with cognitive decline in DLB [29,33,84,85,86▪,87], Recently, highly promising plasma Aβ and phosphorylated tau (p-tau) assays have been developed, offering less invasive and more accessible blood-based biomarkers [88].